专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO02059148A8 A METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC PATHOGEN 审中-公开
标题翻译：用于鉴定，分离和产生抗特异性病原体的方法
公开(公告)号：WO02059148A8
公开(公告)日：2003-01-16
申请号：PCT/EP0200546
申请日：2002-01-21
申请人： CISTEM BIOTECHNOLOGIES GMBH , MEINKE ANDREAS , NAGY ESZTER , AHSEN UWE , KLADE CHRISTOPH , HENICS TAMAS , ZAUNER WOLFGANG , MINH DUC BUI , VYTVYTSKA ORESTA , ETZ HILDEGARD , DRYLA AGNIESZKA , WEICHHART THOMAS , HAFNER MARTIN , TEMPELMAIER BRIGITTE , FRASER CLAIRE M , GILL STEVEN
发明人： MEINKE ANDREAS , NAGY ESZTER , VON AHSEN UWE , KLADE CHRISTOPH , HENICS TAMAS , ZAUNER WOLFGANG , MINH DUC BUI , VYTVYTSKA ORESTA , ETZ HILDEGARD , DRYLA AGNIESZKA , WEICHHART THOMAS , HAFNER MARTIN , TEMPELMAIER BRIGITTE , FRASER CLAIRE M , GILL STEVEN
IPC分类号： G01N33/50 , A61K39/00 , A61K39/39 , A61K39/395 , A61P31/10 , B64C9/02 , C07K14/195 , C07K14/31 , C07K16/12 , C12N15/02 , C12N15/09 , C12N15/10 , C12P21/02 , C12P21/08 , C12Q1/68 , C40B40/02 , G01N33/15 , G01N33/53
CPC分类号： C40B40/02 , A61K39/00 , C07K14/195 , C07K14/31 , C07K16/1271 , C12N15/1037 , C12N15/1041 , C12Q1/6806 , C12Q2527/125 , C12Q2521/537
摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: - providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - screening said at least one expression library with said antibody preparation, - identifying antigens which bind in said screening to antibodies in said antibody preparation, - screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and - optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
摘要翻译：描述了用于鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型动物的疫苗其特征在于以下步骤： - 提供来自所述给定类型动物的血浆池或来自人血浆池或个体血清的抗体制剂，其具有抗所述特定病原体，肿瘤，变应原或组织或宿主的抗体易于自身免疫， - 提供至少一种易于自身免疫的所述特异性病原体，肿瘤，变应原或组织或宿主的表达文库， - 用所述抗体制剂筛选所述至少一种表达文库， - 鉴定结合于对所述抗体制剂中的抗体进行筛选， - 从具有抗体的个体的个体血清中筛选鉴别的抗原针对所述特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主， - 鉴定所述鉴定的抗原的超免疫血清反应性抗原部分，以及哪些超免疫血清反应性抗原与所述单个抗体制剂的相关部分结合所述个体血清和 - 任选地分离所述超免疫血清反应性抗原并通过化学或重组方法产生所述超免疫血清反应性抗原。

2. 发明申请

WO02059148A9 A METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC PATHOGEN 审中-公开
标题翻译：用于鉴定，分离和产生抗特异性病原体的方法
公开(公告)号：WO02059148A9
公开(公告)日：2002-10-31
申请号：PCT/EP0200546
申请日：2002-01-21
申请人： CISTEM BIOTECHNOLOGIES GMBH , MEINKE ANDREAS , NAGY ESZTER , AHSEN UWE , KLADE CHRISTOPH , HENICS TAMAS , ZAUNER WOLFGANG , MINH DUC BUI , VYTVYTSKA ORESTA , ETZ HILDEGARD , DRYLA AGNIESZKA , WEICHHART THOMAS , HAFNER MARTIN , TEMPELMAIER BRIGITTE , FRASER CLAIRE M , GILL STEVEN
发明人： MEINKE ANDREAS , NAGY ESZTER , VON AHSEN UWE , KLADE CHRISTOPH , HENICS TAMAS , ZAUNER WOLFGANG , MINH DUC BUI , VYTVYTSKA ORESTA , ETZ HILDEGARD , DRYLA AGNIESZKA , WEICHHART THOMAS , HAFNER MARTIN , TEMPELMAIER BRIGITTE , FRASER CLAIRE M , GILL STEVEN
IPC分类号： G01N33/50 , A61K39/00 , A61K39/39 , A61K39/395 , A61P31/10 , B64C9/02 , C07K14/195 , C07K14/31 , C07K16/12 , C12N15/02 , C12N15/09 , C12N15/10 , C12P21/02 , C12P21/08 , C12Q1/68 , C40B40/02 , G01N33/15 , G01N33/53
CPC分类号： C40B40/02 , A61K39/00 , C07K14/195 , C07K14/31 , C07K16/1271 , C12N15/1037 , C12N15/1041 , C12Q1/6806 , C12Q2527/125 , C12Q2521/537
摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: - providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - screening said at least one expression library with said antibody preparation, - identifying antigens which bind in said screening to antibodies in said antibody preparation, - screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, - identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and - optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
摘要翻译：描述了用于鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型动物的疫苗其特征在于以下步骤： - 提供来自所述给定类型动物的血浆池或来自人血浆池或个体血清的抗体制剂，其具有抗所述特定病原体，肿瘤，变应原或组织或宿主的抗体易于自身免疫， - 提供至少一种易于自身免疫的所述特异性病原体，肿瘤，变应原或组织或宿主的表达文库， - 用所述抗体制剂筛选所述至少一种表达文库， - 鉴定结合于对所述抗体制剂中的抗体进行筛选， - 从具有抗体的个体的个体血清中筛选鉴别的抗原针对所述特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主， - 鉴定所述鉴定的抗原的超免疫血清反应性抗原部分，以及哪些超免疫血清反应性抗原与所述单个抗体制剂的相关部分结合所述个体血清和 - 任选地分离所述超免疫血清反应性抗原并通过化学或重组方法产生所述超免疫血清反应性抗原。

3. 发明申请

WO02059148A3 A METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC PATHOGEN 审中-公开
标题翻译：用于鉴定，分离和产生抗特异性病原体的方法
公开(公告)号：WO02059148A3
公开(公告)日：2003-07-31
申请号：PCT/EP0200546
申请日：2002-01-21
申请人： INTERCELL AG , MEINKE ANDREAS , NAGY ESZTER , AHSEN UWE , KLADE CHRISTOPH , HENICS TAMAS , ZAUNER WOLFGANG , MINH DUC BUI , VYTVYTSKA ORESTA , ETZ HILDEGARD , DRYLA AGNIESZKA , WEICHHART THOMAS , HAFNER MARTIN , TEMPELMAIER BRIGITTE , FRASER CLAIRE M , GILL STEVEN
发明人： MEINKE ANDREAS , NAGY ESZTER , VON AHSEN UWE , KLADE CHRISTOPH , HENICS TAMAS , ZAUNER WOLFGANG , MINH DUC BUI , VYTVYTSKA ORESTA , ETZ HILDEGARD , DRYLA AGNIESZKA , WEICHHART THOMAS , HAFNER MARTIN , TEMPELMAIER BRIGITTE , FRASER CLAIRE M , GILL STEVEN
IPC分类号： G01N33/50 , A61K39/00 , A61K39/39 , A61K39/395 , A61P31/10 , B64C9/02 , C07K14/195 , C07K14/31 , C07K16/12 , C12N15/02 , C12N15/09 , C12N15/10 , C12P21/02 , C12P21/08 , C12Q1/68 , C40B40/02 , G01N33/15 , G01N33/53
CPC分类号： C40B40/02 , A61K39/00 , C07K14/195 , C07K14/31 , C07K16/1271 , C12N15/1037 , C12N15/1041 , C12Q1/6806 , C12Q2527/125 , C12Q2521/537
摘要： Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans.
摘要翻译：描述了用于鉴定，分离和产生来自特异性病原体，肿瘤，变应原或易于自身免疫的组织或宿主的超免疫血清反应性抗原的方法，所述抗原适用于给定类型动物的疫苗或人类。

4. 发明申请

WO2004024182A3 METHOD FOR ISOLATING HEPATITIS C VIRUS PEPTIDES 审中-公开
标题翻译：用于分离HEPATITIS C病毒肽的方法
公开(公告)号：WO2004024182A3
公开(公告)日：2004-12-23
申请号：PCT/EP0309482
申请日：2003-08-27
申请人： INTERCELL AG , BUSCHLE MICHAEL , HABEL ANDRE , KLADE CHRISTOPH , MATTNER FRANK , OTAVA OLEKSANDR , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , ZINKE SANDRA , KIRLAPPOS HELEN
发明人： BUSCHLE MICHAEL , HABEL ANDRE , KLADE CHRISTOPH , MATTNER FRANK , OTAVA OLEKSANDR , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , ZINKE SANDRA , KIRLAPPOS HELEN
IPC分类号： A61K38/00 , A61K39/00 , A61K39/12 , A61K39/145 , A61K39/29 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/045 , C07K14/11 , C07K14/18 , G01N33/576 , A61K38/04 , A61K38/16 , C07K7/04 , G01N33/50 , G01N33/569
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/292 , A61K2039/525 , A61K2039/57 , C07K7/08 , C07K14/005 , C07K2319/00 , C12N2710/16122 , C12N2760/16122 , C12N2770/24222 , C12N2770/24234 , G01N2500/04 , Y10S930/223
摘要： Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: - providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, -contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, -detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterising the HCV-peptide from said complex.
摘要翻译：描述了一种分离具有与MHC / HLA分子的结合能力的丙型肝炎病毒肽（HP）的方法或包含所述HCV-肽和所述MHC / HLA分子的复合物的方法，其特征在于以下步骤： - 提供HCV池肽，所述池包含结合所述MHC / HLA分子的HCV-肽和不结合所述MHC / HLA分子的HCV-肽， - 用所述HCV-肽池接触所述MHC / HLA分子，由此HCV- 具有与所述MHC / HLA分子的结合能力的肽与所述MHC / HLA分子结合，形成包含所述HCV-肽和所述MHC / HLA分子的复合物，检测并任选地从所述HCV-肽分离所述复合物不结合所述MHC / HLA分子，并且任选地从所述复合物中分离和表征HCV-肽。

5. 发明申请

WO03073097A9 METHOD FOR ISOLATING LIGANDS 审中-公开
标题翻译：分离配体的方法
公开(公告)号：WO03073097A9
公开(公告)日：2003-12-24
申请号：PCT/EP0302005
申请日：2003-02-27
申请人： INTERCELL AG , KLADE CHRISTOPH , SCHALICH JULIANE , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , BIRNSTIEL MAX , AICHINGER GERALD , OTAVA ALEXANDER , MATTNER FRANK
发明人： KLADE CHRISTOPH , SCHALICH JULIANE , VYTVYTSKA ORESTA , ZAUNER WOLFGANG , BIRNSTIEL MAX , AICHINGER GERALD , OTAVA ALEXANDER , MATTNER FRANK
IPC分类号： C12Q1/02 , A61K35/12 , A61K38/00 , A61K39/245 , A61P31/12 , A61P43/00 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/045 , G01N33/50 , A61K39/00 , C07K14/705 , C12N5/06
CPC分类号： C07K7/06 , A61K2039/57 , C07K7/08 , C07K14/005 , C12N2710/16122 , G01N2500/04
摘要： Described is a method for isolating ligands which have a binding capacity to a MHC/HLA molecule or a complex comprising said ligand and said MHC/HLA molecule which method comprises the following steps: - providing a pool of ligands, said pool containing ligands which bind to said MHC/HLA molecule and ligands which do not bind to said MHC/HLA molecule, - contacting said MHC/HLA molecule with said pool of ligands whereby a ligand which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said ligand and said MHC/HLA molecule is formed, - detecting and optionally separating said complex from the ligands which do not bind to said MHC/HLA molecule and - optionally isolating and characterising the ligand from said complex as well as a method for isolating T cell epitopes which have a binding capacity to a MHC/HLA molecule.
摘要翻译：描述了用于分离对MHC / HLA分子或包含所述配体和所述MHC / HLA分子的复合物具有结合能力的配体的方法，所述方法包括以下步骤： - 提供配体库，所述库含有结合配体对所述MHC / HLA分子和不与所述MHC / HLA分子结合的配体， - 使所述MHC / HLA分子与所述配体库接触，由此具有与所述MHC / HLA分子结合能力的配体与所述MHC / HLA分子和包含所述配体和所述MHC / HLA分子的复合物， - 检测并任选地将所述复合物从不与所述MHC / HLA分子结合的配体分离，以及 - 任选地从所述复合物分离和表征配体作为分离对MHC / HLA分子具有结合能力的T细胞表位的方法。

6. 发明申请

WO2005004910A2 HCV VACCINES 审中-公开
标题翻译： HCV疫苗
公开(公告)号：WO2005004910A2
公开(公告)日：2005-01-20
申请号：PCT/EP2004007540
申请日：2004-07-09
申请人： INTERCELL AG , BUSCHLE MICHAEL , FRISCH JUERGEN , KLADE CHRISTOPH , LINGNAU KAREN , ZAUNER WOLFGANG , ZETTLMEISSL GERD
发明人： BUSCHLE MICHAEL , FRISCH JUERGEN , KLADE CHRISTOPH , LINGNAU KAREN , ZAUNER WOLFGANG , ZETTLMEISSL GERD
IPC分类号： A61K39/00 , A61K39/29 , C07K14/18
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/29 , A61K2039/55516 , A61K2039/55561 , C12N2770/24222 , C12N2770/24234
摘要： Disclosed is a Hepatitis C virus (HCV) vaccine comprising at least two epitopes, each from a different hotspot epitope, wherein a hotspot epitope is defined as an epitope containing peptide selected from the group consisting of KFPGGGQIVGGVYLLPRRGPRLGVRATRK, GYKVLVLNPSVAAT, AYAAQGYKVLVLNPSVAAT, DLMGYIP(A/L)VGAPL, GEVQVVSTATQSFLATCINGVCWTV, HMWNFISGIQYLAGLSTLPGNPA, VDYPYRLWHYPCT(V/I)N(F/Y)TIFK(V/I)RMYVGGVEHRL, AAWYELTPAETTVRLR, GQGWRLLAPITAYSQQTRGLLGCIV, IGLGKVLVDILAGYGAGVAGALVAFK, FTDNSSPPAVPQTFQV, LEDRDRSELSPLLLSTTEW, YLVAYQATVCARAQAPPPSWD, MSTNPKPQRKTKRNTNR, LINTNGSWHINRTALNCNDSL, TTILGIGTVLDQAET, FDS(S/V)VLCECYDAG(A/C)AWYE, ARLIVFPDLGVRVCEKMALY, AFCSAMYVGDLCGSV, GVLFGLAYFSMVGNW, VVCCSMSYTWTGALITPC, TRVPYFVRAQGLIRA and TTLLFNILGGWVAAQ.
摘要翻译：公开了一种丙型肝炎病毒（HCV）疫苗，其包含至少两个表位，每个表位各自为不同的热点表位，其中热点表位定义为选自KFPGGGQIVGGVYLLPRRGPRLGVRATRK，GYKVLVLNPSVAAT，AYAAQGYKVLVLNPSVAAT，DLMGYIP（A / L）VGAPL，GEVQVVSTATQSFLATCINGVCWTV，HMWNFISGIQYLAGLSTLPGNPA，VDYPYRLWHYPCT（V / I）N（F / Y）TIFK（V / I）RMYVGGVEHRL，AAWYELTPAETTVRLR，GQGWRLLAPITAYSQQTRGLLGCIV，IGLGKVLVDILAGYGAGVAGALVAFK，FTDNSSPPAVPQTFQV，LEDRDRSELSPLLLSTTEW，YLVAYQATVCARAQAPPPSWD，MSTNPKPQRKTKRNTNR，LINTNGSWHINRTALNCNDSL，TTILGIGTVLDQAET，FDS（S / VLCECYDAG（A / C）AWYE，ARLIVFPDLGVRVCEKMALY，AFCSAMYVGDLCGSV，GVLFGLAYFSMVGNW，VVCCSMSYTWTGALITPC，TRVPYFVRAQGLIRA和TTLLFNILGGWVAAQ。

7. 发明申请

WO2007121491A8 HCV VACCINATIONS 审中-公开
标题翻译： HCV疫苗
公开(公告)号：WO2007121491A8
公开(公告)日：2008-01-10
申请号：PCT/AT2006000166
申请日：2006-04-25
申请人： INTERCELL AG , VON GABAIN ALEXANDER , COHEN KATHERINE , LINGNAU KAREN , GINZLER MICHAEL , TAUBER ERICH , KLADE CHRISTOPH , FORMICA ALESSANDRA , ZAUNER WOLFGANG
发明人： VON GABAIN ALEXANDER , COHEN KATHERINE , LINGNAU KAREN , GINZLER MICHAEL , TAUBER ERICH , KLADE CHRISTOPH , FORMICA ALESSANDRA , ZAUNER WOLFGANG
IPC分类号： A61K38/02 , A61K39/29 , A61K39/39 , A61P31/14 , C07K14/18
CPC分类号： A61K39/29 , A61K39/12 , A61K2039/54 , A61K2039/545 , A61K2039/55511 , A61K2039/55516 , A61K2039/55555 , C07K14/005 , C12N2770/24222 , C12N2770/24234
摘要： The invention relates to a method for preventing or treating Hepatitis C Virus (HCV) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times.
摘要翻译：本发明涉及一种预防或治疗丙型肝炎病毒（HCV）感染的方法，其中将包含有效量的至少一种HCV T细胞抗原和包含肽键的聚阳离子化合物的HCV疫苗给予人类个体性每周至少3次。

8. 发明申请

WO2009030676A2 PHARMACEUTICAL COMPOSITION COMPRISING A JAPANESE ENCEPHALITIS VIRUS FOR ADMINISTRATION TO A SPECIFIC PATIENT POPULATION 审中-公开
标题翻译：包含日本食品病毒的药物组合物用于特定患者人口的管理
公开(公告)号：WO2009030676A2
公开(公告)日：2009-03-12
申请号：PCT/EP2008061527
申请日：2008-09-02
申请人： INTERCELL AG , TAUBER ERICH , DEWASTHALY SHAILESH , KLADE CHRISTOPH , KALTENBOECK ASTRID , SCHULLER ELISABETH
发明人： TAUBER ERICH , DEWASTHALY SHAILESH , KLADE CHRISTOPH , KALTENBOECK ASTRID , SCHULLER ELISABETH
IPC分类号： A61K39/12 , A61P31/14
CPC分类号： A61K39/12 , A61K2039/5252 , A61K2039/55 , A61K2039/55505 , C12N2770/24134
摘要： The present invention relates to a pharmaceutical composition comprising a cell culture derived, inactivated JEV for use in the treatment or prevention of an infection with JEV in a human subject with at least 40 years of age. Furthermore, the invention relates to the use of a cell culture derived, inactivated JEV for the preparation of a pharmaceutical composition for the treatment or prevention of an infection with JEV, wherein the pharmaceutical composition is administered to a human subject with at least 40 years of age. The present invention also relates to a method for treating or preventing an infection with JEV, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition comprising a cell culture derived, inactivated JEV to a human subject with at least 40 years of age. In another aspect, the invention relates to a pharmaceutical composition comprising a JEV for use in the treatment or prevention of an infection with JEV in a subject which has previously been vaccinated with a TBEV vaccine. In still another aspect, the invention relates to the use of a JEV for the preparation of a pharmaceutical composition for the treatment or prevention of an infection with JEV, wherein the pharmaceutical preparation is administered to a subject which has previously been vaccinated with a TBEV vaccine. The invention further relates to a method for treating or preventing an infection with JEV, comprising the steps of administering a therapeutically effective amount of a TBEV vaccine to a subject, and subsequently administering a therapeutically effective amount of a pharmaceutical composition comprising a JEV to said subject.
摘要翻译：本发明涉及一种药物组合物，其包含用于治疗或预防至少40岁的人受试者中JEV感染的细胞培养物衍生的灭活JEV。此外，本发明涉及用于制备用于治疗或预防JEV感染的药物组合物的细胞培养物衍生的灭活JEV的用途，其中所述药物组合物施用于至少40年的人类受试者年龄。本发明还涉及用于治疗或预防JEV感染的方法，包括向至少40岁的人受试者施用治疗有效量的包含细胞培养物衍生的灭活的JEV的药物组合物的步骤。另一方面，本发明涉及一种药物组合物，其包含用于治疗或预防以前用TBEV疫苗接种的受试者中的JEV感染的JEV。另一方面，本发明涉及JEV用于制备用于治疗或预防JEV感染的药物组合物的用途，其中所述药物制剂施用于先前已接种过TBEV疫苗的受试者。本发明还涉及用于治疗或预防JEV感染的方法，包括以下步骤：向受试者施用治疗有效量的TBEV疫苗，然后向所述受试者施用治疗有效量的包含JEV的药物组合物。

9. 发明申请

WO2009024534A2 JAPANESE ENCEPHALITIS VIRUS (JEV) AND TICK-BORNE ENCEPHALITIS VIRUS (TBEV) PEPTIDES STIMULATING HUMAN T CELL RESPONSES 审中-公开
标题翻译： JAPANESE ENCEPHALITIS VIRUS（JEV）和TICK-BORNE ENCEPHALITIS VIRUS（TBEV）PEPTIDES刺激人类T细胞应答
公开(公告)号：WO2009024534A2
公开(公告)日：2009-02-26
申请号：PCT/EP2008060705
申请日：2008-08-14
申请人： INTERCELL AG , SCHARNAGL NICOLE , KLADE CHRISTOPH
发明人： SCHARNAGL NICOLE , KLADE CHRISTOPH
IPC分类号： C07K14/18 , A61K39/12 , A61K39/42
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/70 , C12N2770/24122 , C12N2770/24134
摘要： The present invention provides means for the development of diagnostic assays and pharmaceutical compositions to identify, treat or prevent infections caused by JEV or TBEV. More particularly, the invention relates to T cell epitopes, fragments or variants thereof, complexes comprising said T cell epitopes and at least one additional compound, nucleic acids encoding said T cell epitopes, and T cells specifically recognizing said T cell epitopes, which can be used for said diagnostic assays and pharmaceutical compositions. The invention also relates to pharmaceutical compositions comprising said T cell epitope, complex, nucleic acid, and/or T cell for the treatment or prevention of an infection with JEV and/or TBEV. Furthermore, the present invention provides methods for immunizing an animal or human against an infection with JEV and/or TBEV, and methods for stimulating an immune response in an animal or human against an infection with JEV and/or TBEV. In yet other aspects, the invention provide methods for diagnosing an infection with JEV and/or TBEV and methods for monitoring the immune response of a subject to a JEV vaccine or a TBEV vaccine.
摘要翻译：本发明提供用于鉴定，治疗或预防由JEV或TBEV引起的感染的诊断测定和药物组合物开发的方法。更具体地，本发明涉及T细胞表位，其片段或变体，包含所述T细胞表位和至少一种另外的化合物的复合物，编码所述T细胞表位的核酸和特异性识别所述T细胞表位的T细胞，其可以是用于所述诊断测定和药物组合物。本发明还涉及包含用于治疗或预防感染JEV和/或TBEV的所述T细胞表位，复合物，核酸和/或T细胞的药物组合物。此外，本发明提供了用于免疫动物或人免受JEV和/或TBEV感染的方法，以及用于刺激动物或人体免疫应答以防止JEV和/或TBEV感染的方法。在其它方面，本发明提供用于诊断JEV和/或TBEV的感染的方法以及用于监测受试者对JEV疫苗或TBEV疫苗的免疫应答的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式